<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895920</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS RF001 TRANSBioHIV</org_study_id>
    <nct_id>NCT01895920</nct_id>
  </id_info>
  <brief_title>Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?</brief_title>
  <acronym>TRANSBioHIV</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims at characterizing HIV-1 viral biofilms structural and functional properties&#xD;
      and at deciphering its role as a new viral reservoir and as a new mode of viral spread. The&#xD;
      prospective national study will be conducted on cells isolated from blood samples from 20&#xD;
      patients infected with HIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' preliminary data indicate that besides &quot; free &quot; infectious viral&#xD;
      particles, HIV-1 infected cluster of differentiation 4 (CD4+) lymphocytes also produce&#xD;
      extracellular viral assemblies wrapped in an extracellular matrix cocoon and tightly bound to&#xD;
      the surface of the cell. Importantly, these structures are infectious, transferred to target&#xD;
      cells upon intercellular contacts and they are key role in HIV-1 spread between T&#xD;
      lymphocytes. HIV-1 viral biofilm could be important not only for direct transmission of the&#xD;
      virions but also for &quot; trans-infection &quot;, a process our objectives are:&#xD;
&#xD;
        -  to better characterize the molecular composition and the architecture of this biofilm&#xD;
           (using proteomics, glycomic superresolution cell imaging approaches) with regard to its&#xD;
           properties (infectivity, adhesiveness, protection of virions) and to determine whether&#xD;
           cells from infected patients produce such structures.&#xD;
&#xD;
        -  to delineate the viral factors regulating the formation of these new infectious&#xD;
           structures (with a particular attention on Tat, Vpu and Nef HIV-1 encoded using mutant&#xD;
           viruses or expression vectors).&#xD;
&#xD;
        -  to investigate the lymphocyte pathways regulating the viral biofilms formation and&#xD;
           composition in extracellular matrix (ECM) proteins (using quantitative polymerase chain&#xD;
           reaction (qPCR) and siRNA).&#xD;
&#xD;
        -  to determine whether those viral biofilms are involved in HIV-1 transmission by&#xD;
           transinfection&#xD;
&#xD;
        -  to study the contribution of those infectious structures and the dynamics of their&#xD;
           transmission in lymph nodes.&#xD;
&#xD;
      This project may contribute to decipher the role of viral biofilms in HIV-1 transmission.&#xD;
      Ultimately, we intend to determine how the interference of retroviral infections with T cell&#xD;
      activation pathways modulates the pattern of ECM production by T cells, tuning viral biofilm&#xD;
      composition and regulating viral dissemination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of HIV positive patients with cells producing biofilms.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of cells with biofilms identified among the HIV positive patients presenting such structures.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>HIV infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 HIV infected subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>HIV infection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  able to give written consent&#xD;
&#xD;
          -  HIV positive serology HIV1&#xD;
&#xD;
          -  Viral load &gt; 10 000 copies/ml&#xD;
&#xD;
          -  CD4 T cells &gt; 100 cells/mm3&#xD;
&#xD;
          -  or Treated by antiretroviral therapy (ARV) for less than 6 months&#xD;
&#xD;
          -  Covered by French Social Security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Involved in a clinical trial&#xD;
&#xD;
          -  Pregnancy (inclusion can be postponed)&#xD;
&#xD;
          -  No covered by French Social Security&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service de Médecine Interne, CHU Kremlin-Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Biofilm</keyword>
  <keyword>Transmission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

